2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134268
    8-Br-7-CH-ADPR 1011457-95-6 98%
    8-Br-7-CH-ADPR (8-Bromo-7-deazaadenosine-5'-O-diphosphoribose) is a specific TRPM2 antagonist that inhibits TRPM2 activation by binding to the NUDT9 homology domain of the TRPM2 channel, thereby controlling the influx of cations through the cell membrane channel. 8-Br-7-CH-ADPR can be used to study the role of TRPM2 in pathological processes such as cell death, neurodegenerative diseases, myocardial infarction, and diabetes.
    8-Br-7-CH-ADPR
  • HY-134299
    8-CPT-cAMP-AM 663941-66-0 98%
    8-CPT-cAMP-AM (8-(4-Chlorophenylthio)-cAMP-AM) is an Epac/PKA activator. 8-CPT-cAMP-AM potentiates glucose-dependent first- and second-phase insulin secretion, induces β-cell depolarization, modulates intracellular calcium via influx and ryanodine-sensitive store mobilization, and facilitates calcium-induced calcium release resistant to PKA inhibition. 8-CPT-cAMP-AM can be used for the research of cardiac hypertrophy, diabetic cardiomyopathy, and melanoma.
    8-CPT-cAMP-AM
  • HY-134314
    8-Nitro-cGMP 913645-39-3 98%
    8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice.
    8-Nitro-cGMP
  • HY-134325
    8-OH-cAMP 31356-95-3 98%
    8-OH-cAMP (8-Hydroxy-cAMP) is a polar, membrane-impermeable cyclic adenosine monophosphate analog that is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases. As a polar PKA agonist, 8-OH-cAMP is used to study the role of cAMP in the development and progression of cardiovascular and metabolic diseases.
    8-OH-cAMP
  • HY-134351
    AA-dUTP tetrasodium 85280-65-5 98%
    AA-dUTP tetrasodium is an amine-modified nucleotide that has been used in the synthesis of fluorescently labeled dUTP.
    AA-dUTP tetrasodium
  • HY-134451
    Diethylumbelliferyl phosphate 897-83-6 98%
    Diethylumbelliferyl phosphate (DEUP), a selective and potent inhibitor of cholesterol esterase, does not inhibit protein kinase activity A in vitro, and it effectively disrupts steroidogenesis by blocking the transport of cholesterol into the mitochondria of steroidogenic cells, with an IC50 of 11.6 μM, potentially limiting dietary cholesterol absorption.
    Diethylumbelliferyl phosphate
  • HY-134860
    Prostaglandin D1 alcohol 1176470-37-3 98%
    Prostaglandin D1 (PGD1) alcohol is the synthetic analog of PGD1 with a primary alcohol in place of the C-1 carboxyl.
    Prostaglandin D1 alcohol
  • HY-134999
    10-Hydroxywarfarin 83219-99-2 98%
    10-Hydroxywarfarin, a metabolite of (R)-(+)-Warfarin (HY-W015998 ), is a CYP2C9 and vitamin K epoxide reductase complex 1 (VKOR) inhibitor with IC50s of 1.6 µM and 80 ng/mL, respectively.
    10-Hydroxywarfarin
  • HY-135016
    Oleic acid triethanolamine 2717-15-9 98%
    Oleic acid triethanolamine (9-cis-Octadecenoic acid triethanolamine) is the most common monounsaturated fatty acid found in human adipocytes and other tissues. Oleic acid triethanolamine is a Na+/K+ ATPase activator.
    Oleic acid triethanolamine
  • HY-13507R
    Lumiracoxib (Standard) 220991-20-8 98%
    Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.
    Lumiracoxib (Standard)
  • HY-13524R
    AG-1478 (Standard) 153436-53-4
    AG-1478 (Standard) is the analytical standard of AG-1478. This product is intended for research and analytical applications. AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478 (Standard)
  • HY-135280
    MRL-650 852315-00-5 98%
    MRL-650 (CB1 inverse agonist 1), a chemical probe, is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC50s of 7.5 nM and 4100 nM for CB1 and CB2 receptors, respectively. Anorexigenic effects.
    MRL-650
  • HY-13528R
    Clinofibrate (Standard) 30299-08-2 98%
    Clinofibrate (Standard) is the analytical standard of Clinofibrate. This product is intended for research and analytical applications. Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.
    Clinofibrate (Standard)
  • HY-135298
    Soya fatty acids 68308-53-2
    Soya fatty acids is a class of polyunsaturated fatty acids extracted from soybean.
    Soya fatty acids
  • HY-135376
    Atorvastatin methyl ester 345891-62-5 98.76%
    Atorvastatin methyl ester (Compound 2a) is a methyl esterified derivative of Atorvastatin. Atorvastatin methyl ester inhibits the 9-cis-RA-induced Gal4 reporter activity more strongly than Atorvastatin.
    Atorvastatin methyl ester
  • HY-135505
    JTP-103237 1883864-16-1 98%
    JTP-103237 is a MGAT2 inhibitor (IC50: 0.019 μM and 6.423 μM for hMGAT2 and hMGAT3 respectively). JTP-103237 modulates fat absorption, decreases plasma glucose levels and prevents diet-induced obesity.
    JTP-103237
  • HY-136410
    4-hydroxy Nonenal Mercapturic Acid 146764-24-1 98%
    4-hydroxy Nonenal Mercapturic Acid is a major urinary metabolite of 4-hydroxy-2-nonenal (4-HNE). 4-hydroxy Nonenal Mercapturic Acid metabolites include reduced alcohols, aldehydes, and carboxylic acids, which further form gamma-lactols and gamma-lactones, resulting in 4-5 final urinary metabolites in vivo. 4-hydroxy Nonenal Mercapturic Acid can be used as a biomarker to assess oxidative stress.
    4-hydroxy Nonenal Mercapturic Acid
  • HY-13646R
    Encequidar (Standard) 849675-66-7
    Encequidar (Standard) is the analytical standard of Encequidar. This product is intended for research and analytical applications. Encequidar (HM30181; HM30181A) is a potent and selective inhibitor of P-glycoprotein.
    Encequidar (Standard)
  • HY-136631
    PF-04279405 955881-01-3 98%
    PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC50=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes.
    PF-04279405
  • HY-136679
    TD114-2 436866-52-3 98%
    TD114-2 (cmpound 29) is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β) (IC50=48 nM). TD114-2 is associated with the hydrogen bond formation of arginine 141 (ARG141) specific to GSK-3β, an amino acid that is often a negatively charged residue in other kinases, which determines the high selectivity of GSK-3β. TD114-2 can be used in the study of diabetes, neurodegenerative diseases and other diseases associated with GSK-3β.
    TD114-2
Cat. No. Product Name / Synonyms Application Reactivity